Skip to content
PeptideAgent

Thymulin regulatory status

Current status of Thymulin in the United States: Unscheduled. In sport: WADA prohibited. Details, sources, and the dated timeline follow.

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

What is the current status of Thymulin?

Regulatory: UnscheduledWADA: WADA prohibitedVerified: Verified Sep 22, 2026
FDA and compounding
Not FDA approved and not approved in any country. Thymulin does not appear on the FDA 503A bulks list, in Category 2, or among the withdrawn nominations as of the FDA pages current to April 2026, and it has no USP monograph, so there is no lawful basis for a US compounding pharmacy to dispense it. It was not part of the July 2026 advisory committee review. Products sold online are research chemicals.
WADA
WADA prohibited
Access path
  1. No lawful United States access path identified on the last verified date.
  2. Not available as an FDA approved product, not nominated for the 503A bulks list, and not eligible for compounding under section 503A or 503B.
  3. Products labeled research use only are not lawful for human use and are not verified for identity or purity.

Full Thymulin page: evidence, dosing in the literature, and sources

How has the status of Thymulin changed over time?

No dated regulatory event has been recorded for Thymulin. That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.

Sources

Numbered citations in the answers above point here, followed by the regulatory sources on record for Thymulin and the source of each dated event.

  1. [1]FDA: Bulk drug substances used in compounding under section 503A of the FD&C ActFDA, 2026
  2. [2]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list, content current as of April 22, 2026)FDA, 2026
  3. [3]WADA Prohibited List, section S0 non-approved substancesWADA, 2026